Abstract: An object of the present invention is to provide a pharmaceutical agent which is administered to a patient with chronic kidney disease in which the progress of worsening of renal function is rapid whereby the progress of the symptom is suppressed or improved. The present invention relates to a progress-suppressing or improving agent for chronic kidney disease containing 5-hydroxy-1-methylhydantoin as an active ingredient. The pharmaceutical agent of the present invention showed a significant effect in a patient with chronic kidney disease where progress of the renal function decrease is rapid. The present pharmaceutical agent is very useful as a highly safe pharmaceutical agent which suppresses or improves the progress of worsening of the renal function of a patient with rapidly progressive chronic kidney disease for which there has been no effective therapeutic agent being simply and easily ingestible.

Abstract: An object of the present invention is to provide a pharmaceutical agent which is administered to a patient with chronic kidney disease in which the progress of worsening of renal function is rapid whereby the progress of the symptom is suppressed or improved. The present invention relates to a progress-suppressing or improving agent for chronic kidney disease containing 5-hydroxy-1-methylhydantoin as an active ingredient. The pharmaceutical agent of the present invention showed a significant effect in a patient with chronic kidney disease where progress of the renal function decrease is rapid. The present pharmaceutical agent is very useful as a highly safe pharmaceutical agent which suppresses or improves the progress of worsening of the renal function of a patient with rapidly progressive chronic kidney disease for which there has been no effective therapeutic agent being simply and easily ingestible.

Abstract: A highly safe and useful therapeutic agent for hypoalbuminaemia contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: 1

Abstract: A highly safe and useful therapeutic agent for hypoalbuminaemia contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. Administration of the compounds substantially increases the serum albumin value of patients suffering from hypoalbuminaemia from abnormal values, and significantly improves the condition of hypoalbuminaemia.

Abstract: A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1, and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.

Abstract: Hydantoin derivatives for eliminating free radicals and active oxygen which can be easily made into pharmaceutical preparations, show little, if any side effects, and are capable of being administered by the oral route. The pharmaceutical compositions for eliminating the active oxygen and the free radicals contain at least one hydantoin derivative represented by the following formula (I): wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives which have an action of eliminating the active oxygen and the free radicals are, accordingly, useful as pharmaceutical agents for treating a variety of diseases in which active oxygen and free radicals are involved or play a detrimental role.

Abstract: The present invention provides naphthyridinium derivatives which are effective, for example, in diagnosis of diabetes, diabetic complications, dialysis-related complications, aging, diseases accompanied by aging, etc. and also provides an antibody prepared from said derivative as a hapten. The naphthyridinium derivatives of the present invention are compounds represented by the general formula (I): ##STR1## wherein R and R' may be the same or different and are alkyl groups optionally substituted with at least one amino group, at least one protected amino group, at least one carboxyl group, or combinations thereof, and their pharmaceutically accepted salts. It is possible to conduct the diagnosis of diabetes, diabetic complications, dialysis-related complications, aging, diseases accompanied by aging, etc. using a compound of the present invention as an indicator.

Abstract: The present invention relates to an agricultural and horticultural composition inducing resistance in plants against salt- and water-stresses which comprises as an active ingredient an effective amount of at least one cyclic dipeptide of the following formula (I) or an agriculturally or horticulturally acceptable salt thereof; ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is a hydrogen atom or lower alkyl group, or R.sub.1 and R.sub.2 are joined to form pyrrolidine ring which may optionally have hydroxy group, and R.sub.3 is a hydrogen atom or hydroxy group.

Abstract: The present invention relates to a pharmaceutical composition for use in preventing or treating heart diseases in a mammal, which comprises at least one aminoalkanesulfonic acid derivative of the formula (I): ##STR1## wherein X is hydrogen or an amino acid residue; Y is hydrogen, a phenyl group or an alkyl group, which may have a hydroxy, amino, carboxy, phenyl or hydroxyphenyl group; or X and Y are joined to form a trimethylene or hydroxytrimethylene group; and at least one of X and Y is other than hydrogen;or pharmaceutically acceptable salt thereof.

Abstract: Peptide compounds of formula (I): ##STR1## wherein A is hydrogen or an amino-protecting group; X is a member selected from the group consisting of Gly, Glu, Tyr, Asp, Phe, Ile, Ala, Pro, Leu, Hyp, Val, His, Arg, Ser, Thr, Pyr, Trp, 5-HTP, Cys, Met, .tau.-Glu, .beta.-Asp; Y is a (CH.sub.2).sub.3-6 or (CH.sub.2).sub.3-6 having an hydroxy group; R is an hydroxy group or an oxygen atom with a carboxy-protecting group; are useful as neurotropic agents.

Abstract: The present invention relates to a method for preventing or treating renal failure in a mannal which comprises administering the mammal an effective amount for renal failure of at least one hydantoin derivative of the following formula (I) or a pharmaeutically acceptable salt thereof.

Abstract: The glycocyamidine derivatives of the present invention are represented by the following formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, is hydrogen or a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl, and R represents hydrogen or an acetyl group,which are useful as test reagents for diagnosis of renal failure.

Abstract: The glycocyamidine derivatives of the present invention are represented by the following formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, is hydrogen or a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl, and R represents hydrogen or an acetyl group.which are useful as test reagents for diagnosis of renal failure.

Abstract: The present invention relates to a novel dipeptide having the formula (I): ##STR1## wherein R represents hydrogen atom or an amino-protecting group, Y represents hydrogen atom or hydroxy group which may optionally have protecting group, and X represents an acidic amino acid residue which may optionally have at least one protecting group; and pharmaceutical acceptable salt thereof. These dipeptides are useful as plant growth regulator.

Abstract: Pharmaceutical compositions containing an oxaluric acid derivative of the formula: ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen; an alkyl group or a cycloalkyl group; or R.sub.1 and R.sub.2 are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached; and R.sub.3 is hydrogen or an alkyl group. These compounds have excellent hypoglycemic effects with low toxcicity and safety.

Abstract: The present invention is concerned with novel acylindole derivatives of the formula (I) and platelet-aggregation inhibiting agents containing them as an active ingredient. ##STR1## In the formula (I), either R.sub.1 and R.sub.2 is hydrogen, an alkyl group having 1 to 5 carbon atoms, an alkyl group substituted by at least one hydroxy group and having 1 to 5 carbon atoms, or a group of the formula ##STR2## in which R.sub.3 is an alkyl group having 1 to 5 carbon atoms, and --OR.sub.2 is a substituent at the ortho or para position.The compounds of the invention are useful as preventive medicine or remedy for various diseases or symptoms caused by platelet-aggregation, as well as inhibitors of platelet-aggregation on vascular walls during or after an operation.

Abstract: Pharmaceutical compositions containing imidazolidinetrione derivatives or pharmaceutically acceptable salts thereof having hypoglycemic and hypolipidemic effects. The compositions comprise as an active ingredient at least one imidazolidinetrione derivative of the formula: ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, an alkyl group, a cycloalkyl group or ##STR2## and each of R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, halogen, a nitro group, a lower alkyl group or a lower alkoxy group.

Abstract: The present invention relates to novel hydantoin derivatives represented by the general formula (I) and pharmaceutical compositions containing them as an active ingredient. ##STR1## In the formula (I), X is hydrogen or a group having the formula --OR.sub.4, and each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group.Hydantoin derivatives and pharmaceutically acceptable salts thereof of the present invention have excellent hypoglycemic, hypolipidemic and diuretic effects, as well as low toxicity and great safety. Therefore, the compounds of the present invention are not only useful as antidiabetics but also as drugs for hyperlipidemia.